Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 14/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.48 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4425102 | 0.85 | MLYCD (0.61) | MLYCDLMNASMN1; SMN2NR1H2NR1H3 | |
| SCHEMBL4875535 | 0.85 | MLYCD (0.61) | MLYCDLMNASMN1; SMN2NR1H2NR1H3 | |
| Hydrochloric Acid SCHEMBL4425100 | 0.84 | MLYCD (0.60) | MLYCDLMNASMN1; SMN2NR1H2NR1H3 | |
| SCHEMBL2942980 | 0.79 | MLYCD (0.64) | MLYCDLMNASMN1; SMN2 | |
| SCHEMBL3235441 | 0.78 | MLYCD (1.00) | MLYCD | |
| SCHEMBL4883103 | 0.77 | MLYCD (0.63) | MLYCDNR1H2NR1H3 | |
| SCHEMBL2937273 | 0.77 | MLYCD (0.66) | MLYCDLMNASMN1; SMN2 | |
| SCHEMBL2945327 | 0.77 | MLYCD (0.75) | MLYCDLMNASMN1; SMN2NR1H2NR1H3 | |
| SCHEMBL11625955 | 0.77 | MLYCD (0.66) | MLYCDLMNASMN1; SMN2 | |
| SCHEMBL11622162 | 0.73 | MLYCD (0.60) | MLYCDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070869-A1 | Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-03-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070869-A1 | Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | MLYCD, ME3, ACACA | MLYCD 1/4885LMNA 3668/4885SMN1; SMN2 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.